ð ç« æ«éèš
Cardiogenic Shock
- Definition: inadequate CO + hypoperfusion despite adequate volume
- BP < 90, CI < 1.8-2.2, PCWP > 15-18
- End-organ hypoperfusion
Etiology
- AMI (75-80%) + mechanical complications (papillary rupture, VSR, free wall rupture)
- ADHF, cardiomyopathy, myocarditis, valvular, arrhythmia, tamponade, massive PE
SCAI Classification
- A (at risk) â B (pre-shock) â C (classic) â D (deteriorating) â E (extremis)
Initial Management
- Recognition + SCAI staging
- Echocardiogram + coronary angiography (AMI)
- Inotrope (dobutamine) + vasopressor (norepinephrine)
- MCS if refractory
- Shock team consultation
Mechanical Circulatory Support
- IABP: limited evidence (IABP-SHOCK II); less used
- Impella: catheter-based LV pump; improved with DanGER-SHOCK 2024
- VA-ECMO: full cardiopulmonary support; refractory shock + biventricular failure
- ECPELLA: ECMO + Impella for severe biventricular
- BiPella: biventricular Impella
AMI + Cardiogenic Shock
- Primary PCI + culprit-only initially (CULPRIT-SHOCK)
- Mechanical complications: emergent surgery
- MCS bridging
Right Ventricular MI
- Inferior MI + V4R
- Fluid resuscitation + avoid NTG/morphine
- Inotrope if RV failure
Key Trials
- IABP-SHOCK II: no benefit IABP
- CULPRIT-SHOCK: culprit-only PCI
- DanGER-SHOCK 2024: Impella improves mortality
- SOAP II: norepinephrine vs dopamine (less arrhythmia, similar mortality)
Shock Teams (2024)
- Multidisciplinary, earlier MCS, improved outcomes
Outcomes
- 40-50% mortality
- Improving with modern therapy + shock teams + MCS
ç§é«åž« hint
- Cardiogenic shock = TIME-CRITICAL (door-to-support time)
- AMI + shock: emergency PCI + Impella consideration
- Norepinephrine first-line vasopressor; dobutamine first-line inotrope
- Mechanical complications post-MI: emergent surgery
- RV MI: fluids + avoid vasodilators
- Shock team activation for high-acuity cases
- VA-ECMO: consider LV decompression (Impella combo)